Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC

This is a prospective phase 2 study to use Functional Precision Oncology (FPO) to predict, prevent and treat early metastatic recurrence in subjects with HR-low/Her2 negative or triple negative breast cancer.

Trial Details

NCT ID

NCT05464082

Phase

PHASE2

Sponsor

University of Utah

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

Functional Precision Oncology

Locations (sample)

Salt Lake City, Utah, United States|40.76078,-111.89105

Key Eligibility Criteria

Subject aged ≥ 18 years.
Subject has Stage I-III disease.
Histologically or cytologically confirmed invasive breast carcinoma that is triple negative (TNBC) or hormone receptor (HR)-low/Her2 negative
-TNBC is defined as:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →